Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (DE:37Z)
FRANKFURT:37Z
Holding DE:37Z?
Track your performance easily
37Z Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.57 - €2.99
Previous Close€0.6
Volume0.00
Average Volume (3M)1.10K
Market Cap
€50.93M
Enterprise Value-€27.38M
Total Cash (Recent Filing)$123.12M
Total Debt (Recent Filing)$36.58M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 11, 2024EPS Estimate
-€0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding88,850,713
10 Day Avg. Volume0
30 Day Avg. Volume1,100
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
€2.52Price Target Upside319.98% Upside
Rating ConsensusHold
Number of Analyst Covering7
Allakos News
Bulls Say, Bears Say
Bulls Say
Efficacy IndicatorsSkin biopsies show >90% Siglec-6 receptor occupancy with a 70% occupancy translating to potent mast cell inhibition.
Financial StabilityThe company ended the quarter with $123M in cash, which management estimates provides sufficient runway into mid-2026.
Safety ProfileSingle and multiple IV doses of AK006 up to 720mg were well-tolerated with no serious adverse events (SAEs) or treatment-emergent AEs leading to drug discontinuation.
Bears Say
Clinical DataThe lack of pharmacodynamic data was the likely cause for ALLK trading down following this update.
Competitive LandscapeCSU has become an increasingly crowded space in the past two years and competitive programs have indicated that mast cell activity is a critical driver of the disease.
Stock PerformanceInvestor expectations were for tryptase depletion and mast cell inhibition data, which was not disclosed, and this led to stock dropping by 28%.
---
37Z FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was €0.57 and its highest was €2.99 in the past 12 months.
What is Allakos Inc’s market cap?
Currently, no data Available
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is Nov 11, 2024 which is in 64 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Aug 07, 2024. The company reported -€0.271 earnings per share for the quarter, beating the consensus estimate of -€0.301 by €0.03.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -€0.23.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 88,850,716 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -€0.271 in its last earnings report, beating expectations of -€0.301. Following the earnings report the stock price went down -10.623%.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Platinum Investment Management. It holds Allakos Inc’s shares valued at 1M.
---
Allakos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.52 (319.98% Upside)
€2.52 (319.98% Upside)
Blogger Sentiment
Bearish
DE:37Z Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $87.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.40%
12-Months-Change
Fundamentals
Return on Equity
-121.54%
Trailing 12-Months
Asset Growth
-50.98%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
37Z Stock 12 Month Forecast
Average Price Target
€2.52
▲(319.98% Upside)
Technical Analysis
Allakos
―
Adaptimmune Therapeutics
―
AnaptysBio
―
Blueprint Medicines
―
Corvus Pharmaceuticals
―
Best Analysts Covering 37Z
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+49.02%
upgraded a buy rating 9 months ago
Copying Tim Lugo's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +49.02% per trade.
---